Hi {{lead.First Name:default=edit me}},

You can leverage our 70,000+ research-ready participant network to obtain leukocyte-enriched apheresis products (leukopaks) from patients with confirmed disease or healthy donors. Customers tell us leukopaks are a game changer for their research by:

  • Improving the accuracy of process development parameters
  • Addressing rare cell abundance issues
  • Streamlining assay development and validations

How would up to 10 billion PBMCs from a single donor with comprehensive medical data promote your ability to deliver for your customers and augment your development and manufacturing business?

Please check out our leukopaks page to learn how you can leverage our unique patient-centric approach to biospecimen procurement or hit reply to contact me directly.

Warm regards,

Brian Neman
CEO and Co-Founder
Sanguine Biosciences | Massachusetts